Description of a Computer Program to Assess Cancer Antigen 15.3, Carcinoembryonic Antigen, and Tissue Polypeptide Antigen Information during Monitoring of Metastatic Breast Cancer

Abstract It is time-consuming to process and compare the clinical and marker information registered during monitoring of breast cancer patients. To facilitate the assessment, we developed a computer program for interpreting consecutive measurements. The intraindividual biological variation, the analytical precision profile, the cutoff limit, and the detection limit for each marker are entered and stored in the program. The assessment procedure for marker signals considers the analytical and biological variation of the applied markers. The software package contains a database that can store the interpretation of the measurements as evaluation codes together with patient demographics, information about treatment type, dates for treatment periods, control periods, and evaluation codes for clinical activity of disease. The consecutive concentrations for a patient are imported temporarily into the program from outside sources and presented graphically. Marker concentrations to be compared are selected with the computer mouse and the significance of the difference is calculated by the program. The program has an option for calculating the lead time of marker signals vs clinical information. The program facilitates the monitoring of individual breast cancer patients with tumor marker measurements. It may also be implemented in trials investigating the utility of potential new markers in breast cancer as well as in other malignancies.

Download Full-text

Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: A phase II study

Medical and Pediatric Oncology ◽

10.1002/(sici)1096-911x(200001)34:1<10::aid-mpo2>3.0.co;2-a ◽

2000 ◽

Vol 34 (1) ◽

pp. 10-13 ◽

Cited By ~ 4

Author(s):

Getta Fried ◽

Moshe E. Stein ◽

Nissim Haim

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Oral Administration ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Clinical Activity ◽

Breast Cancer Patients ◽

Previously Treated

Download Full-text

Evaluation of the Effect of Combination Chemotherapy with Five-day Infusion of Fluorouracil Plus Vinorelbine in Pretreated Metastatic Breast Cancer Patients

QJM ◽

10.1093/qjmed/hcab103.015 ◽

2021 ◽

Vol 114 (Supplement_1) ◽

Author(s):

Tarek Kamel ◽

Mai Ezz El Din ◽

Ahmed Nagy ◽

Rasha Salah

Keyword(s):

Breast Cancer ◽

Continuous Infusion ◽

Cancer Patients ◽

Combination Chemotherapy ◽

Metastatic Breast ◽

Clinical Activity ◽

Breast Cancer Patients ◽

Previously Treated ◽

Treated Breast ◽

Treated Breast Cancer

Abstract Background continuous infusion (CI) of 5-fluorouracil (5-FU) has proven in several studies to be an active and well tolerated treatment for advanced pretreated breast cancer. Navelbine has also shown activity in this setting. Aim This is retrospective study to evaluate the clinical activity and side effects of a combination chemotherapy consisting of a five-day continuous infusion of fluorouracil and i.v. vinorelbine in metastatic previously treated breast cancer patients. Patients and Methods Fifty-four patients received 5FU 600 mg/m2/d for 5 consecutive days as a continuous infusion and vinorelbine 25 mg/m2 on days 1 and 5 as a short intravenous (I/V) infusion every 3 weeks. Results Eleven (20.4%) complete responses, 20 (37%) partial responses and 14 (25.9%) stationary disease were documented, accounting for a clinical benefit rate of 83.3%. The median progression free survival was 6.8 months. The median overall survival was 25.8 months. Treatment was well tolerated, with Grade 3 anemia, febrile neutrobenia and stomatitis in 9.3%, 5.6% and 1.9% respectively as the main toxic reactions. Conclusions: This drug combination is active in metastatic previously treated breast cancer patients with acceptable toxicity profile.

Download Full-text

Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series

Journal of Oncology ◽

10.1155/2012/198412 ◽

2012 ◽

Vol 2012 ◽

pp. 1-6 ◽

Cited By ~ 3

Author(s):

Vincenzo Di Lauro ◽

Elena Torrisi ◽

Ettore Bidoli ◽

Daniela Quitadamo ◽

Sara Cecco ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Response Rate ◽

Target Therapy ◽

Metastatic Breast ◽

Clinical Activity ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Heavily Pretreated

Trastuzumab-based regimes improved clinical outcome in women with overexpressing HER2 metastatic breast cancer, mainly due to the availability of different combination therapies, clinically active and well tolerated. In this study we retrospectively evaluated clinical activity and toxicity of trastuzuamb plus gemcitabine regimen in heavily pretreated HER2 positive metastatic breast cancer patients. Although the observed population was heavily pretreated, the evaluated regimen was notably effective in terms of response rate, time to progression and survival, with very mild toxicity. These data suggest that in over expressing HER2 metastatic breast cancer patients, sequential trastuzumab based chemotherapeutic regimens can achieve good response rate with prolonged TTP in responding patients, even after other target therapy such as lapatinib based combinations.

Download Full-text